Nymox Pharmaceutical Corporation
NYMXF
$0.0751
-$0.0049-6.13%
OTC PK
| 12/31/2024 | 09/30/2024 | 12/31/2023 | 12/31/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -8.84M | -8.84M | -5.33M |
| Total Depreciation and Amortization | -- | -- | 169.00K | 170.30K | 221.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | 3.80M | 3.80M | 270.60K |
| Change in Net Operating Assets | -- | -- | 821.00K | 821.00K | 383.00K |
| Cash from Operations | -- | -- | -4.06M | -4.06M | -4.45M |
| Capital Expenditure | -- | -- | -3.00K | -3.00K | -3.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -3.00K | -3.00K | -3.00K |
| Total Debt Issued | -- | -- | 1.75M | 1.75M | 750.00K |
| Total Debt Repaid | -- | -- | -173.00K | 827.00K | -233.00K |
| Issuance of Common Stock | -- | -- | 1.15M | 1.00M | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -850.00K | -1.74M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 1.74M |
| Cash from Financing | -- | -- | 2.73M | 2.73M | 517.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -1.33M | -1.33M | -3.94M |